Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) dropped 1.8% during trading on Monday . The company traded as low as $5.32 and last traded at $5.37, with a volume of 1,451,818 shares. The stock had previously closed at $5.47.

PGNX has been the subject of a number of research reports. Brean Capital restated a “buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a research report on Tuesday, March 15th. Jefferies Group reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a report on Friday, June 10th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Progenics Pharmaceuticals in a report on Monday, April 4th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 7th. Finally, BTIG Research reduced their price target on Progenics Pharmaceuticals from $12.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, March 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $10.35.

The firm’s 50-day moving average price is $4.76 and its 200 day moving average price is $4.71. The company’s market cap is $375.61 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.05. The firm earned $2.50 million during the quarter, compared to the consensus estimate of $3.27 million. The company’s revenue for the quarter was up 908.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.15) EPS. On average, analysts predict that Progenics Pharmaceuticals Inc. will post $0.12 earnings per share for the current fiscal year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.